GSK plc (LON:GSK) Stock Has Consensus Price Target of GBX 2,064.38

GSK plc (LON:GSK) has received an average rating of “Hold” from the eight research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is GBX 2,064.38.

Several equities analysts recently weighed in on the stock. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research note on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a research note on Tuesday. Berenberg Bank lifted their price target on GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a report on Tuesday, September 15th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a GBX 1,975 price target on shares of GSK in a research report on Tuesday, September 8th.

Insiders Place Their Bets

In related news, insider Jonathan Symonds bought 1,500 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was bought at an average price of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal bought 637 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were bought at an average price of GBX 4,985 per share, with a total value of £31,754.45. Over the last ninety days, insiders have acquired 2,144 shares of company stock valued at $6,009,566. Company insiders own 0.20% of the company’s stock.

GSK Price Performance

Shares of LON GSK opened at GBX 1,779.50 on Wednesday. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73. The business has a 50-day moving average of GBX 1,879.72 and a 200-day moving average of GBX 1,940.95. The stock has a market capitalization of £71.30 billion, a price-to-earnings ratio of 15.11, a PEG ratio of 1.24 and a beta of 0.29. GSK has a fifty-two week low of GBX 1,592 and a fifty-two week high of GBX 2,282.

GSK (LON:GSK) last released its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. As a group, sell-side analysts predict that GSK will post 175.980975 earnings per share for the current fiscal year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.